140 patents
Page 2 of 7
Utility
Methods and Compositions for Improving Kidney Function In Patients with Hepatorenal Syndrome
23 Feb 23
The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease.
Khurram Jamil, Stephen Chris Pappas, Peter Teuber
Filed: 28 Oct 22
Utility
Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
21 Feb 23
The present disclosure provides pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties.
Alex Micka, Kai Feng, Tsz Chung Lai, Jonathan Gaik
Filed: 11 Aug 20
Utility
Methods of Using Inhaled Nitric Oxide Gas for Treatment of Acute Respiratory Distress Syndrome In Children
2 Feb 23
Described herein is a treatment of acute respiratory distress syndrome (ARDS) using incremental dosing of nitric oxide.
Jim Potenziano, Ronald Bronicki
Filed: 15 Jul 22
Utility
Method for Generating Immunoregulatory Cells In a Blood-derived Sample
26 Jan 23
The present invention relates to a method comprising the steps of provision of a sample derived from a blood sample of a subject that has received a checkpoint-inhibitor therapy and is suspected of developing or has developed symptoms of immune-related adverse events (irAE), adding a photosensitizing agent to the sample, and subjecting the sample to irradiation, which preferably generates immunoregulatory NK cells in said sample.
Robert Zeiser, Petya Apostolova, Justus Duyster
Filed: 17 Dec 20
Utility
Apparatus and method for detecting liquid level in a clear or partially clear container
17 Jan 23
A trap bowl is provided to accumulate liquid droplets from a filter, as a liquid content.
Scott I. Biba
Filed: 23 Dec 19
Utility
Systems and methods for manufacturing and safety of an NO
17 Jan 23
The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy.
Jaron M. Acker, Thomas Kohlmann
Filed: 3 Jul 19
Utility
Method of Identifying and Treating Premature Infants at Risk for BPD
5 Jan 23
Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD).
Douglas Stuart Greene, Joseph J. Medicis, Jim Potenziano
Filed: 12 Sep 22
Utility
Systems and methods for delivery of therapeutic gas
20 Dec 22
Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient.
Jaron M. Acker, Jeff Milsap, Robin Roehl, Jeffrey Schmidt, Craig R. Tolmie
Filed: 21 Jan 20
Utility
Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
6 Dec 22
The present disclosure provides pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties.
Alex Micka, Kai Feng, Tsz Chung Lai, Jonathan Gaik
Filed: 7 Jun 18
Utility
Dosages and Uses of Ornithine Phenylacetate for Treating Hyperammonemia
17 Nov 22
Embodiments of the present disclosure relate to doses of ornithine phenylacetate for treating or ameliorating hyperammonemia and the methods of administrating the same in a patient with a chronic liver disease, for example, cirrhosis.
Xiaofeng Wang Rears, Jack Tseng, Carmen Mak, Nagaraju Poola, Regis Vilchez, Aniruddha Potnis, Susan VanMeter, Jan Stange
Filed: 15 Oct 20
Utility
Administration and Monitoring of Nitric Oxide In Ex Vivo Fluids
10 Nov 22
Described are systems and methods for monitoring administration of nitric oxide (NO) to ex vivo fluids.
Jim Potenziano, Douglas R. Hansell, Jeff Griebel, Eddie Costa, Lisa Cooper, David William Newman
Filed: 13 Jul 22
Utility
Abuse deterrent immediate release capsule dosage forms
25 Oct 22
Capsule dosage forms that provide immediate release of active ingredients and have abuse deterrent properties.
Tsz Chung Lai, Rebecca Sue Walker, Chirag Patel, Jaehan Park
Filed: 18 Sep 19
Utility
Systems and method for delivery of therapeutic gas to patients in need thereof using enhanced breathing circuit gas (BCG) flow measurement
18 Oct 22
The present invention generally relates to systems and method for delivery of therapeutic gas to patients in need thereof using enhanced breathing circuit gas (BCG) flow measurement.
Jaron M. Acker, Craig R. Tolmie
Filed: 22 Jan 19
Utility
Method of identifying and treating premature infants at risk for BPD
18 Oct 22
Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD).
Douglas Stuart Greene, Joseph J. Medicis, Jim Potenziano
Filed: 27 Feb 20
Utility
Spray dried compositions having different dissolution profiles and processes for their preparation
11 Oct 22
The present disclosure provides compositions having different dissolution profiles.
Joseph M. Davis, Robert C. Cuca, Edward J. Beasley
Filed: 27 May 15
Utility
Apparatus and method for humidity conditioning sample gas of a patient breathing circuit affiliated with a ventilator and/or nitric oxide delivery system
27 Sep 22
A therapeutic gas is administered to a patient.
John P. Stanton, John V. Berndt
Filed: 28 Oct 19
Utility
Extended release, abuse deterrent dosage forms
20 Sep 22
Extended release, abuse deterrent dosage forms comprising crush-resistant controlled-release particles that provide abuse deterrent properties to the dosage forms.
Jonathan Gaik, Jaehan Park, Ryan Lathrop, Gary Nichols, John Schallom
Filed: 13 Mar 20
Utility
Administration and monitoring of nitric oxide in ex vivo fluids
16 Aug 22
Described are systems and methods for monitoring administration of nitric oxide (NO) to ex vivo fluids.
Jim Potenziano, Douglas R. Hansell, Jeff Griebel, Eddie Costa, Lisa Cooper, David William Newman
Filed: 23 Apr 20
Utility
Methods of Assessing Hepatic Encephalopathy
11 Aug 22
The present disclosure relates to methods of treating or ameliorating hepatic encephalopathy (HE), including assessing the severity of HE in a patient suffering from HE, or the determining the presence or occurrence of an overt hepatic encephalopathy event.
Stanley Bukofzer, Regis Vilchez
Filed: 7 May 20
Utility
Formulations of L-ornithine Phenylacetate
30 Jun 22
Some embodiments of the present application are directed to oral formulations of L-ornithine phenylacetate and methods of using the same.
Laurene Wang, Stanley Bukofzer, Linda S. Grais
Filed: 6 Jan 22